[Benign mesothelial tumors].

Abstract readEnglish AbstractReviewReview

In one paragraph

Review in Pathologie (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.4field-weighted citation impact, top 37% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Iris TischoffInstitut für Pathologie, Ruhr-Universität Bochum an den Universitätskliniken Bergmannsheil, Bürkle-de-la-Camp Platz 1, 44789, Bochum, Deutschland. iris.tischoff@rub.de.ORCID http://orcid.org/0009-0002-6452-2732

Anja TheileInstitut für Pathologie, Ruhr-Universität Bochum an den Universitätskliniken Bergmannsheil, Bürkle-de-la-Camp Platz 1, 44789, Bochum, Deutschland.

BG University Hospital Bergmannsheil Bochum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign mesothelial tumors are rarer than malignant mesotheliomas and are often found in the peritoneum as incidental findings in women. They include the adenomatoid tumor (AT), the well-differentiated mesothelial tumor (WDPMT), the mesothelioma in situ (MIS), and the solid papillary mesothelial tumor (SPMT). ATs are always benign and predominantly manifest in the genital tract. WDPMTs can develop multifocally and are prone to recurrence, particularly in the case of incomplete resection. Only MISs are considered a confirmed precursor lesion of malignant mesothelioma according to the currently valid World Health Organization (WHO) classifications. As with malignant mesothelioma, alterations of BAP1, MTAP, and p16 are detectable for MIS in contrast to the other three tumors. SPMTs cannot be clearly assigned to the other mesothelial tumors and have so far only been described in the peritoneum in women with a benign course.

Indexed as

Genital Neoplasms, FemaleNeoplasms, MesothelialPeritoneal NeoplasmsCyclin-Dependent Kinase Inhibitor p16FemaleHumansPurine-Nucleoside PhosphorylaseTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16MTAP protein, humanPurine-Nucleoside PhosphorylaseTumor Suppressor ProteinsUbiquitin ThiolesteraseAdenomatoidtumorGenital tractMalignant mesotheliomMesotheliom in situStroma invasion

Identifiers

PMID38695911

DOI10.1007/s00292-024-01333-6

OpenAlexW4396582212

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.